President John Kennedy famously said that a rising tide lifts all boats, and that is looking to be the case in today’s ...

At this time, I would like to welcome everyone to Karyopharm Therapeutics third quarter 2024 financial results conference ...

The Company's partner, Incyte, is now recruiting patients for a Phase 2, open-label, randomized, multicenter trial of axatilimab in combination with ruxolitinib in patients ≥12 years of age with newly ...

The full abstracts are now available through the ASH conference website. Pursuant to Disc Medicine practice, the clinical ...

Myelodysplastic Neoplasms (MDS)” “Hematological Improvement and Other Clinical Benefits of Elritercept as Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the ...

Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

0:09 | The 4 approved drugs have different [adverse] effects. Ruxolitinib [Jakafi] is most known for the cytopenias that it causes, and same with fedratinib [Inrebic]. For both of them, anemia, ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.

Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...